Year:  2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 

PQRS Measure

 This measure may be submitted via Registry only

The following codes apply for this PQRS measure:

CPT Codes

CodeModifierPOSDescription
11600N/AN/AExcision, malignant lesion including margins, trunk, arms, or legs; excised diameter 0.5 cm or less
11601N/AN/AExcision, malignant lesion including margins, trunk, arms, or legs; excised diameter 0.6 to 1.0 cm
11602N/AN/AExcision, malignant lesion including margins, trunk, arms, or legs; excised diameter 1.1 to 2.0 cm
11603N/AN/AExcision, malignant lesion including margins, trunk, arms, or legs; excised diameter 2.1 to 3.0 cm
11604N/AN/AExcision, malignant lesion including margins, trunk, arms, or legs; excised diameter 3.1 to 4.0 cm
11606N/AN/AExcision, malignant lesion including margins, trunk, arms, or legs; excised diameter over 4.0 cm
11620N/AN/AExcision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.5 cm or less
11621N/AN/AExcision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.6 to 1.0 cm
11622N/AN/AExcision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 1.1 to 2.0 cm
11623N/AN/AExcision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 2.1 to 3.0 cm
11624N/AN/AExcision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 3.1 to 4.0 cm
11626N/AN/AExcision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter over 4.0 cm
11640N/AN/AExcision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.5 cm or less
11641N/AN/AExcision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.6 to 1.0 cm
11642N/AN/AExcision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 1.1 to 2.0 cm
11643N/AN/AExcision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 2.1 to 3.0 cm
11644N/AN/AExcision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 3.1 to 4.0 cm
11646N/AN/AExcision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter over 4.0 cm
14000N/AN/AAdjacent tissue transfer or rearrangement, trunk; defect 10 sq cm or less
14001N/AN/AAdjacent tissue transfer or rearrangement, trunk; defect 10.1 sq cm to 30.0 sq cm
14020N/AN/AAdjacent tissue transfer or rearrangement, scalp, arms and/or legs; defect 10 sq cm or less
14021N/AN/AAdjacent tissue transfer or rearrangement, scalp, arms and/or legs; defect 10.1 sq cm to 30.0 sq cm
14040N/AN/AAdjacent tissue transfer or rearrangement, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; defect 10 sq cm or less
14041N/AN/AAdjacent tissue transfer or rearrangement, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; defect 10.1 sq cm to 30.0 sq cm
14060N/AN/AAdjacent tissue transfer or rearrangement, eyelids, nose, ears and/or lips; defect 10 sq cm or less
14061N/AN/AAdjacent tissue transfer or rearrangement, eyelids, nose, ears and/or lips; defect 10.1 sq cm to 30.0 sq cm
14301N/AN/AAdjacent tissue transfer or rearrangement, any area; defect 30.1 sq cm to 60.0 sq cm
17311N/AN/AMohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; first stage, up to 5 tissue blocks
17313N/AN/AMohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; first stage, up to 5 tissue blocks
5050F2PN/ATreatment plan communicated to provider(s) managing continuing care within 1 month of diagnosis (ML)
5050F3PN/ATreatment plan communicated to provider(s) managing continuing care within 1 month of diagnosis (ML)
5050FN/AN/ATreatment plan communicated to provider(s) managing continuing care within 1 month of diagnosis (ML)
5050F8PN/ATreatment plan communicated to provider(s) managing continuing care within 1 month of diagnosis (ML)
99201N/AN/AOffice or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.
99202N/AN/AOffice or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using total time on the date of the encounter for code selection, 15 minutes must be met or exceeded.
99203N/AN/AOffice or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using total time on the date of the encounter for code selection, 30 minutes must be met or exceeded.
99204N/AN/AOffice or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using total time on the date of the encounter for code selection, 45 minutes must be met or exceeded.
99205N/AN/AOffice or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using total time on the date of the encounter for code selection, 60 minutes must be met or exceeded.
99212N/AN/AOffice or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using total time on the date of the encounter for code selection, 10 minutes must be met or exceeded.
99213N/AN/AOffice or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using total time on the date of the encounter for code selection, 20 minutes must be met or exceeded.
99214N/AN/AOffice or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using total time on the date of the encounter for code selection, 30 minutes must be met or exceeded.
99215N/AN/AOffice or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using total time on the date of the encounter for code selection, 40 minutes must be met or exceeded.
5050F2PN/ATreatment plan communicated to provider(s) managing continuing care within 1 month of diagnosis (ML)
5050F3PN/ATreatment plan communicated to provider(s) managing continuing care within 1 month of diagnosis (ML)
5050FN/AN/ATreatment plan communicated to provider(s) managing continuing care within 1 month of diagnosis (ML)
5050F8PN/ATreatment plan communicated to provider(s) managing continuing care within 1 month of diagnosis (ML)

ICD9 Codes

CodeModifierPOSDescription
172.0N/AN/AMalignant melanoma of skin of lip
172.1N/AN/AMalignant melanoma of skin of eyelid, including canthus
172.2N/AN/AMalignant melanoma of skin of ear and external auditory canal
172.3N/AN/AMalignant melanoma of skin of other and unspecified parts of face
172.4N/AN/AMalignant melanoma of skin of scalp and neck
172.5N/AN/AMalignant melanoma of skin of trunk, except scrotum
172.6N/AN/AMalignant melanoma of skin of upper limb, including shoulder
172.7N/AN/AMalignant melanoma of skin of lower limb, including hip
172.8N/AN/AMalignant melanoma of other specified sites of skin
172.9N/AN/AMelanoma of skin, site unspecified
172.0N/AN/AMalignant melanoma of skin of lip
172.1N/AN/AMalignant melanoma of skin of eyelid, including canthus
172.2N/AN/AMalignant melanoma of skin of ear and external auditory canal
172.3N/AN/AMalignant melanoma of skin of other and unspecified parts of face
172.4N/AN/AMalignant melanoma of skin of scalp and neck
172.5N/AN/AMalignant melanoma of skin of trunk, except scrotum
172.6N/AN/AMalignant melanoma of skin of upper limb, including shoulder
172.7N/AN/AMalignant melanoma of skin of lower limb, including hip
172.8N/AN/AMalignant melanoma of other specified sites of skin
172.9N/AN/AMelanoma of skin, site unspecified

ICD10CM Codes

CodeModifierPOSDescription
C43.0N/AN/AMalignant melanoma of lip
C43.10N/AN/AMalignant melanoma of unspecified eyelid, including canthus
C43.11N/AN/AMalignant melanoma of right eyelid, including canthus
C43.12N/AN/AMalignant melanoma of left eyelid, including canthus
C43.20N/AN/AMalignant melanoma of unspecified ear and external auricular canal
C43.21N/AN/AMalignant melanoma of right ear and external auricular canal
C43.22N/AN/AMalignant melanoma of left ear and external auricular canal
C43.30N/AN/AMalignant melanoma of unspecified part of face
C43.31N/AN/AMalignant melanoma of nose
C43.39N/AN/AMalignant melanoma of other parts of face
C43.4N/AN/AMalignant melanoma of scalp and neck
C43.51N/AN/AMalignant melanoma of anal skin
C43.52N/AN/AMalignant melanoma of skin of breast
C43.59N/AN/AMalignant melanoma of other part of trunk
C43.60N/AN/AMalignant melanoma of unspecified upper limb, including shoulder
C43.61N/AN/AMalignant melanoma of right upper limb, including shoulder
C43.62N/AN/AMalignant melanoma of left upper limb, including shoulder
C43.70N/AN/AMalignant melanoma of unspecified lower limb, including hip
C43.71N/AN/AMalignant melanoma of right lower limb, including hip
C43.72N/AN/AMalignant melanoma of left lower limb, including hip
C43.8N/AN/AMalignant melanoma of overlapping sites of skin
C43.9N/AN/AMalignant melanoma of skin, unspecified
D03.0N/AN/AMelanoma in situ of lip
D03.10N/AN/AMelanoma in situ of unspecified eyelid, including canthus
D03.11N/AN/AMelanoma in situ of right eyelid, including canthus
D03.12N/AN/AMelanoma in situ of left eyelid, including canthus
D03.20N/AN/AMelanoma in situ of unspecified ear and external auricular canal
D03.21N/AN/AMelanoma in situ of right ear and external auricular canal
D03.22N/AN/AMelanoma in situ of left ear and external auricular canal
D03.30N/AN/AMelanoma in situ of unspecified part of face
D03.39N/AN/AMelanoma in situ of other parts of face
D03.4N/AN/AMelanoma in situ of scalp and neck
D03.51N/AN/AMelanoma in situ of anal skin
D03.52N/AN/AMelanoma in situ of breast (skin) (soft tissue)
D03.59N/AN/AMelanoma in situ of other part of trunk
D03.60N/AN/AMelanoma in situ of unspecified upper limb, including shoulder
D03.61N/AN/AMelanoma in situ of right upper limb, including shoulder
D03.62N/AN/AMelanoma in situ of left upper limb, including shoulder
D03.70N/AN/AMelanoma in situ of unspecified lower limb, including hip
D03.71N/AN/AMelanoma in situ of right lower limb, including hip
D03.72N/AN/AMelanoma in situ of left lower limb, including hip
D03.8N/AN/AMelanoma in situ of other sites
D03.9N/AN/AMelanoma in situ, unspecified
C43.0N/AN/AMalignant melanoma of lip
C43.10N/AN/AMalignant melanoma of unspecified eyelid, including canthus
C43.11N/AN/AMalignant melanoma of right eyelid, including canthus
C43.12N/AN/AMalignant melanoma of left eyelid, including canthus
C43.20N/AN/AMalignant melanoma of unspecified ear and external auricular canal
C43.21N/AN/AMalignant melanoma of right ear and external auricular canal
C43.22N/AN/AMalignant melanoma of left ear and external auricular canal
C43.30N/AN/AMalignant melanoma of unspecified part of face
C43.31N/AN/AMalignant melanoma of nose
C43.39N/AN/AMalignant melanoma of other parts of face
C43.4N/AN/AMalignant melanoma of scalp and neck
C43.51N/AN/AMalignant melanoma of anal skin
C43.52N/AN/AMalignant melanoma of skin of breast
C43.59N/AN/AMalignant melanoma of other part of trunk
C43.60N/AN/AMalignant melanoma of unspecified upper limb, including shoulder
C43.61N/AN/AMalignant melanoma of right upper limb, including shoulder
C43.62N/AN/AMalignant melanoma of left upper limb, including shoulder
C43.70N/AN/AMalignant melanoma of unspecified lower limb, including hip
C43.71N/AN/AMalignant melanoma of right lower limb, including hip
C43.72N/AN/AMalignant melanoma of left lower limb, including hip
C43.8N/AN/AMalignant melanoma of overlapping sites of skin
C43.9N/AN/AMalignant melanoma of skin, unspecified
D03.0N/AN/AMelanoma in situ of lip
D03.10N/AN/AMelanoma in situ of unspecified eyelid, including canthus
D03.11N/AN/AMelanoma in situ of right eyelid, including canthus
D03.12N/AN/AMelanoma in situ of left eyelid, including canthus
D03.20N/AN/AMelanoma in situ of unspecified ear and external auricular canal
D03.21N/AN/AMelanoma in situ of right ear and external auricular canal
D03.22N/AN/AMelanoma in situ of left ear and external auricular canal
D03.30N/AN/AMelanoma in situ of unspecified part of face
D03.39N/AN/AMelanoma in situ of other parts of face
D03.4N/AN/AMelanoma in situ of scalp and neck
D03.51N/AN/AMelanoma in situ of anal skin
D03.52N/AN/AMelanoma in situ of breast (skin) (soft tissue)
D03.59N/AN/AMelanoma in situ of other part of trunk
D03.60N/AN/AMelanoma in situ of unspecified upper limb, including shoulder
D03.61N/AN/AMelanoma in situ of right upper limb, including shoulder
D03.62N/AN/AMelanoma in situ of left upper limb, including shoulder
D03.70N/AN/AMelanoma in situ of unspecified lower limb, including hip
D03.71N/AN/AMelanoma in situ of right lower limb, including hip
D03.72N/AN/AMelanoma in situ of left lower limb, including hip
D03.8N/AN/AMelanoma in situ of other sites
D03.9N/AN/AMelanoma in situ, unspecified
Legend:
ClaimThis measure can be submitted via claim. Use the 'Data Collection' pdf associated with the measure.
GroupThis measure can be submitted through one or more groups. Click on the group name to view the group information.
RegistryThis measure can be submitted through registry.
EHRThis measure can be submitted via Electronic Health Record (EHR).
GPRO/ACOThis measure can be submitted via Group Practice Reporting Option, or GPRO Web Interface.
SurveyThis measure can be submitted/collected via a Certified Survey Vendor.

More information on these alternative reporting mechanisms is available at:
    http://www.cms.gov/PQRS/20_AlternativeReportingMechanisms.asp.
demo
request yours today
subscribe
start today
newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.